Mainolfi Nello 4

4 · Kymera Therapeutics, Inc. · Filed Feb 25, 2026

Insider Transaction Report

Form 4

Period: 2026-02-25

Kymera Therapeutics, Inc.KYMR

Mainolfi Nello

DirectorChief Executive Officer

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-02-25$2.08/sh+30,000$62,400→ 696,195 total
Sale
Common Stock
[F1][F2]
2026-02-25$89.78/sh−19,764$1,774,412→ 676,431 total
Sale
Common Stock
[F1][F3]
2026-02-25$90.39/sh−5,434$491,179→ 670,997 total
Sale
Common Stock
[F1][F4]
2026-02-25$91.76/sh−3,293$302,166→ 667,704 total
Sale
Common Stock
[F1][F5]
2026-02-25$92.81/sh−1,501$139,308→ 666,203 total
Sale
Common Stock
[F1]
2026-02-25$93.49/sh−8$748→ 666,195 total
Exercise/Conversion
Stock Option (Right to Buy)
[F1][F6]
2026-02-25−30,000→ 245,559 total
Exercise: $2.08Exp: 2029-11-13→ Common Stock (30,000 underlying)

Footnotes (6)

[F1]These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person.
[F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.16 to $90.14, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.16 to $90.83, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.295 to $92.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.20 to $93.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F6]The shares underlying this stock option are fully vested and exercisable.

Signature

/s/ Bruce Jacobs, as Attorney-in-Fact|2026-02-25

Documents

1 file

4
ownership.xmlPrimary
4